Sanctuary Advisors LLC Has $27.02 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Sanctuary Advisors LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.9% during the first quarter, Holdings Channel.com reports. The firm owned 54,969 shares of the medical research company’s stock after buying an additional 1,559 shares during the period. Sanctuary Advisors LLC’s holdings in Thermo Fisher Scientific were worth $27,019,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. High Note Wealth LLC increased its stake in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $28,000. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $29,000. Olistico Wealth LLC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $29,000. Finally, Birchwood Financial Partners Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $29,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $535.72 on Thursday. The firm has a market capitalization of $199.08 billion, a PE ratio of 29.45, a PEG ratio of 2.37 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 1 year low of $403.36 and a 1 year high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm’s fifty day simple moving average is $481.81 and its 200 day simple moving average is $515.01.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Insider Buying and Selling

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a report on Monday, July 6th. Stifel Nicolaus reduced their target price on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating for the company in a research note on Friday, April 24th. Finally, HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average price target of $602.14.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.